Can a drug stop dangerous side effects of new myeloma therapies?
NCT ID NCT07657312
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatments. The study will enroll 35 adults who have already tried at least four prior therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
infliximab
What this could lead to
If successful, this could provide a way to prevent severe side effects from newer myeloma treatments, making them safer and more tolerable.
What could go wrong
This is a small early-phase trial with only 35 participants, so results may not apply broadly. Infliximab itself can cause infections or allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact